Who Supplies Escitalopram to India from DENMARK

Importing finished pharmaceutical formulations containing Escitalopram into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The foreign manufacturer must obtain a valid manufacturing or wholesale drug license from the country of origin. An Importer License is mandatory for the Indian importer, issued by the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO) by submitting Form 40 or 41, along with a No Objection Certificate (NOC) from the manufacturer. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for import drug registration varies but typically ranges from 6 to 12 months. Specific requirements for Escitalopram formulations under HS Code 30049099 include detailed product information, manufacturing process details, and compliance with Indian Pharmacopoeia standards.

Imported finished pharmaceutical formulations containing Escitalopram must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV, is necessary to ensure product efficacy and safety. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. Failure to meet these requirements can result in delays, rejections, or destruction of the consignment.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Denmark have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for Danish pharmaceutical products. These developments aim to balance the promotion of domestic industry with the need for high-quality imported formulations.

India imports finished Escitalopram formulations to meet the demand for branded and patented products not manufactured domestically. Specific dosage forms, such as extended-release tablets or combination therapies, may not be produced locally, necessitating imports. Despite a robust domestic pharmaceutical industry, certain specialized formulations are sourced from abroad to fulfill market needs. The market size for Escitalopram in India is substantial, with a growing patient base requiring consistent and high-quality supply.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, and a Secondary Higher Education Cess of 1%, totaling 13%. Additionally, a Countervailing Duty (CVD) of 6% is applicable, bringing the total duty to 19%. The Social Welfare Surcharge (SWS) is 10%, and the Integrated Goods and Services Tax (IGST) is applicable as per the prevailing GST rates. Anti-dumping duties may apply if the product is subject to such measures. Exemption notifications can reduce the total landed duty percentage, depending on specific conditions and product classifications.

India sources finished Escitalopram formulations from Denmark due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms not produced domestically. Denmark's pharmaceutical industry is known for innovation, particularly in the development of novel drug delivery systems and combination therapies. While other suppliers like China, Germany, and the United States also export to India, Denmark's emphasis on quality and specialized formulations provides a competitive advantage. Denmark's share in India's pharmaceutical imports is significant, reflecting its established presence and reputation in the market.

India imports finished Escitalopram formulations from Denmark due to the country's advanced pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms not produced domestically. Denmark's emphasis on innovation and quality ensures a consistent supply of high-quality products, meeting the specific needs of the Indian market. The importation of these formulations is strategic, aiming to provide patients with access to effective treatments that may not be available through domestic production.

When compared to other origins such as China, Germany, and the United States, Denmark offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. Denmark's pharmaceutical industry is known for its stringent quality control measures and adherence to international standards, ensuring the safety and efficacy of its products. While other countries may offer lower prices, Denmark's focus on quality and compliance provides a unique advantage for Indian importers seeking reliable and high-quality pharmaceutical formulations.

Indian importers face several supply chain risks when sourcing finished pharmaceutical formulations from Denmark, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, closely monitoring currency exchange rates, staying updated on regulatory changes, implementing robust quality assurance processes, and establishing contingency plans for potential shipping disruptions. Proactive risk management strategies are essential to ensure a consistent and reliable supply of pharmaceutical products.